Healthcare Industry News: Glaucoma
News Release - June 14, 2007
STAAR Surgical Creates New Leadership Position to Oversee Research, Development and Clinical ActivitiesCraig Felberg Brings 25 Years of Medical Device & Product Development Experience to STAAR
MONROVIA, Calif., June 14 (HSMN NewsFeed) -- STAAR Surgical Company (Nasdaq: STAA ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that Craig Felberg, who served as Research and Development Program Director for Refractive Products at Bausch & Lomb from 2000 to 2006, has been appointed STAAR's Vice President of Research Development and Clinical. Mr. Felberg's appointment to the newly created position is effective June 18, 2007 and he will report to David Bailey, President and CEO of STAAR Surgical.
"We consider ourselves very fortunate to attract an executive with Craig's expertise and background to STAAR as we focus on solid operational execution worldwide," said Mr. Bailey. "Craig's experience with operations, research, product development and clinical trials in the ophthalmology industry, along with his past working relationship with many members of the current STAAR senior management team, makes him an ideal fit for our organization. During the past few months Craig has guided our product development and project management as a consultant, and based on that experience we expect his leadership to have an immediate and positive impact on our Company."
Mr. Felberg joined Bausch and Lomb in 1995 as Vice President of the Company's California Operations. In 2000, he became Research and Development Program Director for Refractive Products and oversaw all activities associated with research, preclinical development, new product development, project management and clinical affairs for refractive products. Prior to joining Bausch & Lomb, Mr. Felberg was the Vice President of Operations at Johnson & Johnson's Iolab Division in Southern California and was Plant Manager of Alcon Surgical's Pomona, California plant.
"STAAR Surgical has tremendous potential with both its existing products already on the market and its products under development. During the past few months, I've gotten to know the team that I'll be working with and believe that we will achieve excellence in all areas of product development and clinical affairs," said Mr. Felberg.
Mr. Felberg earned an MBA from Pepperdine University in Malibu, California and a BA in Management from the University of Redlands.
About STAAR Surgical
STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and Glaucoma. STAAR's ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More than 65,000 ICLs have been sold worldwide. More information is available at http://www.staar.com.
All statements in this press release that are not statements of historical fact are forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations and any statements regarding the development or introduction of new products or the success of existing products, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of adapting our largely independent marketing model to the challenges of the refractive market, our ability to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the willingness of surgeons and patients to adopt a new product and procedure, and our ability to successfully market the ICL in the U.S. while overcoming the foregoing challenges, and other factors beyond our control, including those detailed from time to time in our reports filed with the Securities and Exchange Commission. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.
Source: STAAR Surgical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.